Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Retroviruses

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Drug Dosage Regimen: Overview

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial.

Nature communications·2025

Same author

SARS-COV-2 Infection in People Living with HIV: Experience from a Tertiary Hospital in Madrid.

AIDS research and human retroviruses·2021

Same author

Virological Outcome Measures During Analytical Treatment Interruptions in Chronic HIV-1-Infected Patients.

Open forum infectious diseases·2020

Same author

Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B.

Vaccines·2019

Same author

Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.

PloS one·2018

Same author

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.

PloS one·2017

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

[Tenofovir DF in rescue regimens].

Juan Carlos López Bernaldo de Quirós¹

¹Unidad de Enfermedades Infecciosas/VIH, Hospital Universitario Gregorio Marañón, Madrid, España. juanclopezbq@wanadoo.es

Enfermedades Infecciosas Y Microbiologia Clinica

|February 7, 2009

Summary

Tenofovir (TDF) drug activity is impacted by specific mutations in the reverse transcriptase gene, particularly thymidine analogue mutations (TAMs). The 65R mutation is now a signature mutation for TDF therapy.

Area of Science:

Virology
Molecular Biology
Pharmacology

Context:

Nucleoside analogues, including tenofovir (TDF), are crucial in antiviral therapy.
Drug resistance through mutations in the reverse transcriptase gene can affect TDF efficacy.
Understanding these mutations is vital for optimizing TDF treatment outcomes.

Purpose:

To analyze the impact of various reverse transcriptase mutations on tenofovir (TDF) activity.
To identify specific mutations that confer resistance or affect TDF efficacy.
To evaluate the clinical significance of these mutations in patients undergoing TDF therapy.

Summary:

Tenofovir (TDF) efficacy is influenced by nucleoside analogue mutations (NAMs), especially thymidine analogue mutations (TAMs).
The number and type of TAMs, particularly type 1 mutations like 41L and 210W, significantly reduce TDF activity.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Experiment Videos

Last Updated: Jun 25, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

The 65R mutation, initially linked to zalcitabine, is now a signature mutation for TDF, selected during treatment.

While 41L and 210W mutations are associated with poorer outcomes in TDF rescue therapy, type 2 TAMs have minimal impact.

Conversely, the 184V mutation correlates with a more favorable virologic response in TDF-treated patients.

Impact:

Provides critical insights into drug resistance mechanisms for tenofovir (TDF).
Informs clinical decision-making for antiviral rescue therapy in patients with pre-existing mutations.
Highlights the varying impact of different reverse transcriptase mutations on TDF effectiveness, aiding personalized treatment strategies.